Migraine Drugs Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025

Migraine Drugs Market Overview :

Migraine is a neurological disorder that causes severe pain in head and results in nausea, vomiting, and extreme sensitivity to light and sound. The common types of migraine are with aura and without aura that means classical migraines and common migraines. Women are more prone to this disease than men. Therapeutic agents such as anti-inflammatory drugs (NSAIDs), for example aspirin, ibuprofen, sumatriptan, zolmitriptan, naproxen, antisickness medicines and many more drugs are used to cure or lower the migraine. The symptoms of migraine can begin in childhood or in adulthood and it may progress through four stages such as prodrome, aura, headache and post- drome. Whereas aura occurs before or during a migraine, it is a symptom of nervous system that usually leads to visual disturbance such as flashes of light or zigzag vision. In this visual disturbance, around 20 to 60 minutes vision loss occurs, also the pins, needles sensation in arms can be felt. Furthermore, it may lead to difficulty in speaking and can cause for uncontrollable movements of body.

The factors that trigger migraines include hormonal changes in female body, salty food and processed food, alcohol drinks, medications such as oral contraceptive and vasodilators for example nitroglycerin can cause migraines. Latest technology such as a new, smartphone controlled wireless patch has been devised that uses electrical stimulation to reduce the pain of migraines is going to be a revolutionary for migraine patients.

Fill the form for an exclusive sample of Migraine Drugs Market @ https://www.coherentmarketinsights.com/insight/request-sample/575

Migraine drugs market taxonomy

Global Migraine Drugs Market by Drugs Type:

  • Painkillers

  • Ergotamine

  • Triptans

  • Ant nausea drugs

  • Opioids

  • Beta-Blockers

  • Calcium Channel Blocker

  • Antidepressants

Global Migraine Drugs Market by Geography:

  • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

Emerging drugs expected to boost the growth of migraine drugs market in the near future

The launch of new drugs in market is expected to boost the margarine drugs market in the forecast period. For example, the Indian pharmaceutical company Cadila Healthcare Ltd. (Zydus Cadila) received the final approval on June 20, 2017, from the Food and Drug Administration (FDA) to market Eletriptan Hydrobromide tablets (20 mg and 40 mg), which is used in the treatment of migraine.

Furthermore, another Indian pharmaceutical company Novartis has filed its migraine drug erenumab with the European Medicines Agency (EMA) on June 21, 2017. Which is expected to put other pharmaceutical companies into racing to develop a new drug for the treatment of migraine.

Teva Pharmaceuticals Industries Ltd. an Israeli multinational pharmaceutical company which expected to file approval for fremanezumab (TEV-48125) drug by Food and Drug Administration (FDA) later this year (2017). This drug will be used in chronic migraine and the episodic migraine treatment, and this drug is expected to commercialize in market by the second half of 2018.

Migraine disorders are among the most common disorders of the nervous system, it has been almost seen in adult population. Furthermore, North America holds the largest share in the migraine drug market as it holds the large number of ageing population, according to the U.S. Census Bureau in 2013 the aging population was around 14.1%As per World Health Organization (WHO) in 2016, globally it has been estimated that 50% of migraine disorders was found and percentage of this disorders is found high in women due to the hormonal influences. Also, according to the National Headache Foundation (NHF), people from the U.S. spend more than US$ 4 billion annually on drugs in the treatment of migraine pain. The factors influencing for migraine drugs market include increase in awareness about migraine treatment drugs and advancement in technology in the development of migraine drugs.

According to the Migraine Research Foundation (MRF), migraine is a common neurological disease, around 38 million population including men, women and children in the U.S and 1 billion population around the globe is affected by it as of 2017. Excessive consumption of alcohol and increase in consumption of oral contraceptives significantly increases number of migraine disorder cases.

Request for table of content : https://www.coherentmarketinsights.com/ongoing-insight/toc/575

Migraine Drugs Market Key Players Includes:

The increased focus on drug development expected to support the market expansion of migraine drugs market players. There are various players across the globe running into the competition includes Endo International plc, Pfizer Inc., Aegis Therapeutics, LLC., Aeriel BioPharma, Alder BioPharmaceuticals Inc., Amgen Inc., Astellas Pharma Inc., CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., IntelGenx Corp., Johnson & Johnson, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Teva Pharmaceutical Industries LTD., Valeant Pharmaceuticals International, Inc., WINSTON PHARMACEUTICALS, Inc., Zogenix Inc., Abbott Laboratories, AstraZeneca plc, and GlaxoSmithKline plc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Advertisements

Global Stairlifts Market – Growth, Trends, and Forecasts (2017–2025)

Stairlifts Market Overview:

Stairlifts are the mechanical devices that is use to lift people up and down over the staircase which runs along a rail or track in home care settings or healthcare facilities. Stairlifts are also known variously as chair lifts or stair gliders. Stairlifts are motorized seats which are powered by alternating current or batteries so they can function even when there is no power cut. Stairlifts is available for both straight and curved staircases are available in market that can be customized. Stairlifts are easy to operate and also have different features which includes safety belt or harness, flip-up rail, swivel seat, limit sensors handheld controller, rechargeable batteries and call stations. Stairlifts are installed for disabled or people suffering from musculoskeletal disorders due to aging.

Fill the form for an exclusive sample of Stairlifts Market report @ https://www.coherentmarketinsights.com/insight/request-sample/471

Furthermore, factors such as ease of accessibility, low cost of installation, rise in geriatric population and aging-related health conditions such as hip fractures, traumatic brain injuries, Vitamin D deficiency, vision problems or lower body weakness. According to World Population Ageing Report 2015, the number of people in the world aged 60 years or over are projected to grow by 56%, from 901 million to 1.4 billion from 2015 to 2030. Straight rails are used on domestic staircase usually made up of aluminum or steel. Whereas, carriage is also an important component which moves along the rail and normally runs on small diameter roller. Stairlifts carriage include seat with arms and a footrest which has special platform known as “perch” seat for the users with shorter legs to make the stairlifts more comfortable to sit on. Stairlifts carriage can also be customized according to needs of individual, additionally stairlifts are controlled by using a control on the arm of the lift and to satisfy the safety codes stairlifts have cut-out switches connected to safety edges and also other protective devices are provided.

Global Stairlifts Market Taxonomy

By Product Type

  • Straight Stairlifts

  • Curved Stairlifts

  • Standing Stairlifts

By Modality Type

  • Indoor

  • Outdoor

By Operation Mode

  • Alternating Current

  • Direct Current

By End-User

  • Health Care Facilities

  • Home Care Settings

Rising global geriatric population fuels the growth of global stairlifts market

Common problems faced by geriatric population include instances of falling due to vertigo or dizziness, metal deterioration, chronic diseases and reduced mobility caused due to age-related issue. According to W.H.O falls are the second leading cause of accident or unintentional injury which leads to death of people worldwide whereas adults older than 65 years suffer the greatest number of fatal falls. Furthermore, every 11 seconds, an older adult is treated in emergency room for a fall and every 19 minutes, an elderly person dies from a fall according to National Council on Aging. Where stairlifts is proving to be an essential mobility devices among the disabled people and geriatric population.

Regional growth engines of stairlifts market

There are about 18.2 million people unable to walk in U.S. according to Centers for Disease and Prevention (CDC) in year 2015 which is expected to boost the market of stairlifts market in U.S. Whereas North America is also seen to increase the market of stairlifts due to rise in geriatric population and also due to advancement in technological development for mobility device marketing. Older people had 18.9% share in Europe according to Eurostat in 2015 which as increased by 0.4% by previous year 2014 which indicates that there will be significant increase in stairlifts market in Europe. Decrease in its installation cost favors the growth in Asia Pacific market of stairlifts.

Request for table of content : https://www.coherentmarketinsights.com/ongoing-insight/toc/471

Key players supporting the growth factor of stairlifts market

Key players operating in the global stairlifts market include Acorn Stairlifts, Bruno Independent Living Aids, Stannah Stairlifts Ltd., Inc, and Handicare. Leading brands available in the market include, Siena, Handicare Van Gogh, Starla, Elan Indoor Straight, and Acorn Superglide 120.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Anesthesia and Respiratory Devices Market Future Trends and Scope Analysis By 2025 |

Anesthesia and Respiratory Devices Market Overview:

Anesthesia is a state in which a person has temporary induced loss of sensation or awareness provided by the anesthesia devices. Anesthesia device provide accurate and continuous supply of medical gases mixed with an accurate concentration of anesthetic vapor. Anesthesia provides painless performance of medical procedures that could serve intolerable pain to an un-anesthetized patient. There are three types of anesthesia general anesthesia, sedation anesthesia and regional or local anesthesia. While respiratory devices are used to provide medication or to comfort patient who have difficulty in breathing and cannot acquire sufficient level of oxygen to maintain life. Patient with respiratory disease use various respiratory devices that help to remove the mucus from the airway and improve the function of pulmonary. Respiratory devices lead the market as compared with anesthesia device as anesthesia devices has limited end user.

Furthermore, increase in aging population who suffer from asthma, pulmonary disease and chronic obstructive pulmonary disease is expected to favor the anesthesia and respiratory device market. According to world ageing population reports in the U.S. between 2015 and 2030, the number of people in the world aged 60 years or over is projected to grow by 56 per cent, from 901 million to 1.4 billion, and by 2050, the global population of older persons is projected to more than double its size in 2015, reaching nearly 2.1 billion. Increase in number of surgeries worldwide also fuels the anesthesia and respiratory device market. Moreover, continuous technical advancement in anesthesia and respiratory devices is another driving force for the growth of market.

Fill the form for an exclusive sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/532

Anesthesia and respiratory devices market taxonomy

By Product Type

  • Anesthesia Devices

  • Anesthesia Machines

  • Anesthesia Disposables

  • Respiratory Devices

  • Respiratory Equipment

  • Respiratory Disposables

  • Respiratory Measurement Devices

By End User

  • Anesthesia Devices

  • Hospital

  • Ambulatory Surgical Centers

  • Respiratory Devices

  • Hospital

  • Ambulatory Surgical Centers

  • Homecare Settings

Rise in number of surgeries fuel the anesthesia and respiratory device market

Anesthesia devices are used commonly in all types of surgeries as they are designed to provide an accurate and continuous supply of mixed medical gases with anesthetic vapors which is delivered to patient at a safe pressure and flow. According to Centers for Disease Control and Prevention in year 2010, 16 million operative procedures were performed in the U.S. whereas rise in number of patient who suffer from respiratory disease favors growth of the market. According to the Center for Disease Control and Prevention in year 2016 estimated that 24 million people, including more than 6 million children have asthma in the U.S.

Furthermore, demand for anesthesia devices are rapidly increased due to growth in safety awareness and technology enhancement. Moreover, Obstructive sleep apnea also favor the growth of market as this type of apnea occurs to throat muscles when they relax, which leads to blockage of airway during sleep and so to the treat OBA disorder respiratory devices are used.

Regional growth engines of the anesthesia and respiratory device market

In terms of geography anesthesia and respiratory device market is segmented into North America, Europe, Asia Pacific, Middle East, Latin America and Africa. Due to presence of high income and health awareness in North America favors the growth of market. Additionally, the leading cause of death in North America is chronic obstructive pulmonary disease (COPD) as it is the third leading cause of death in North America. The above statistics supports the growth of anesthesia and respiratory device market.

Furthermore, due to economic development, health reform by government and increase in investment in research and development in Asia Pacific region is expected to show growth in the market.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/532

The key players dominating the global anesthesia and respiratory device market

Providers in the market offer a broad range of anesthesia and respiratory device and introduction of low priced multi-featured devices in market is increasing the product competition in market within the manufactures. The key player operating the market of anesthesia and respiratory device includes Fisher & Paykel Healthcare, Invacare, GE Healthcare, Teleflex, Philips Healthcare, Drägerwerk AG, Medtronic, Smiths Medical, OSI systems and Getinge AB.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Fetal Monitoring Market – Growth, Trends, and Forecasts (2017–2025)

Fetal Monitoring Market Overview:

Fetal monitoring devices are used to monitor the heart rate and movement of the fetus and maternal contractions. In medical terms, fetal monitoring is imperative to constantly monitor health of the unborn baby and ensure a safe birth. Fetal monitoring measures the heart rate of the baby. Healthcare providers perform fetal monitoring during late pregnancy and labor, as that process is crucial for keeping the mother and the child safe and healthy. These are also used to monitor chronic mental retardation, hypothermia, lung diseases, neonatal diseases, vision & hearing problems, and jaundice. Fetal monitoring is usually done using handheld doppler device or an electronic fetal monitor. Fetal monitoring is necessary to avoid complications during labor or if patient gets an epidural or if oxytocin is required to induce or augment labor.  Moreover there are two ways to perform fetal monitoring namely, external and internal. Fetal monitoring is especially helpful if the patient is expected to have a high-risk pregnancy, especially women suffering from high blood pressure or diabetes.

Get a trending sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/466

Furthermore, the devices are used to check if pre-tern labor medicines are affecting the baby. Fetal monitoring devices are also used in other tests, which includes contraction stress test, non-stress test and biophysical profile that includes the combination of non-stress test and ultrasound. Uterine contractions or pushing during the second stage of labor also affects heart rate of the fetus and thus, fetal monitoring devices play a vital role through the process..

Fetal monitoring market taxonomy

By product type

  • Ultrasound

  • 2D Ultrasound

  • 3D & 4D Ultrasound

  • Doppler Imaging

  • Intrauterine Pressure Catheter (IUPC)

  • Telemetry Solutions

  • Electronic Fetal Monitoring (EFM)

  • External EFM

  • Internal EFM

  • Fetal Electrodes

  • Fetal Doppler

By Methods,

  • Invasive

  • Non-Invasive

By Applications,

  • Antepartum Fetal Monitors

  • Intrapartum Fetal Monitors

By Portability,

  • Portable

  • Non-Portable

By End Users

  • Hospitals

  • Clinics

Increase in birth rate fuels the growth of fetal monitoring market

The boost in fetal monitoring market is due to increased rate of birth and pre-tern births. Various government and nongovernment organizations are actively taking initiatives to provide better maternal and fetal care. However, rise in number of problems during pregnancy due to high-blood pressure, diabetes, pre-tern labor medicine affect the fetus. So, fetal monitoring device are used routinely by gynecology and obstetrics interventions to examine fetal health during labor and delivery. Furthermore, advancement in technology such as wireless or real time analysis also expands the market of fetal monitoring devices. The demand of fetal monitoring device is also increased significantly in past few years to reduce intrapartum stillbirths. According to WHO, annually 15 million babies are born pre-tern which leads to death. Pre-tern babies live only till approx. 5 years of age which is also responsible for nearly 1 million deaths in 2015.

Regional growth engines for fetal monitoring market

Asia Pacific is an emerging region for fetal monitoring market, as healthcare awareness is on the rise in the region and the region is the most populous. However, according to stats mention in World Population Prospects: 2015 Revision, the total fertility was pegged at 2.5 children per woman globally. However, there is wide regional difference across the globe that is further expected to offer irregular scenario over the forecast period in fetal monitoring industry. Furthermore, Africa shows the highest fertility at 4.7 children per women. Whereas Europe has the lowest fertility of 1.6 children per women. Both Asia and Latin America and Caribbean have total fertility of 2.2 children per women which can boost the fetal monitoring market.

Request for table of content : https://www.coherentmarketinsights.com/ongoing-insight/toc/466

Major acquisitions to support growth of fetal monitoring market

Rise in support from government for enhanced maternal facilities such as subsidies given by government to expand care in rural area to private not-for-profit organization, in countries like Uganda as they have poor healthcare facilities. Whereas, the Government of the Philippines has also placed health and maternal health high on its political agenda of reform. Moreover, rising investment of company for development of new features for fetal monitoring devices expects to increase the working efficiency of company and broadens its product portfolio. Key players in the fetal monitoring market include ArjoHuntleigh, Inc. (U.S.), C FUJIFILM SonoSite, Inc. (U.S.), GE Healthcare (U.K.), Natus Medical Incorporated (U.S.), Neoventa Medical (Sweden), ovidien PLC (U.S.),Philips Healthcare (Netherlands), Siemens Healthcare (Germany), Analogic Corporation (U.S.), and Spacelabs Healthcare Inc. (U.S.).

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Antibody Drug Conjugates Market — Growth, Trends, and Forecasts (2016–2024)

Antibody Drug Conjugates Market Overview:

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Get an exclusive sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/181

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020

The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates

Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/181

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Infusion Pumps Market worth 5.0 Billion USD by 2024

The Global Infusion Pumps Market was valued at US$ 2,985.5 million in 2015 and is projected to expand at a CAGR of 6.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Increasing number of applications of infusion pumps in the healthcare sector is projected to support growth of the infusion pumps market over the forecast period.

Infusion pump delivers controlled amount of fluid and medications into the bloodstream over a period of time. The drug infusion system includes two components, namely open loop and closed loop. According to a study by Healthcare Human Factors University Health Network, in 2009, around 13% of the hospitals in Ontario used smart pumps and around 6% were in the process of implementing the techniques. Thus, adoption rate of smart large volumetric infusion pumps in Ontario has been low. Infusion pumps have contributed to improvements in patient care at affordable costs. Apart from its wide application in hospitals and for clinical use, the systems are also used in the form of portable device to provide the drug or fluid on the move. Furthermore, the major application that has revolutionized the use of infusion pumps involves diabetes where it works as an insulin pump to provide with the controlled and preset amount of insulin in the patient’s body. According to the fact sheet by W.H.O, number of diabetic patients witness a steep increase from 108 million in 1980 to 422 million in 2014. This in turn is expected to favor the market growth for infusion pumps over the forecast period.

To know the latest trends and insights prevalent in the infusion pumps market, click the link below:

https://www.coherentmarketinsights.com/market-insight/infusion-pumps-market-127

The development of combination in medical device technology and advanced drugs are the precursor for adoption of control infusion therapies, which have increased the use of infusion pumps globally. Currently, there are various clinical applications of infusion pumps that involves life-sustaining along with life-saving treatments under other clinical segments such as anesthesia, intensive care, and oncology. Infusion pumps are used in various settings such as wards, home care environment and hospitals for pain management and other drug related treatments. Furthermore, rapid development of the healthcare infrastructure in emerging economies and upgrade of the same in developed regions creates a highly conducive environment for growth of the infusion pumps market in the near future.

Major players in the global infusion pumps market are laying emphasis on product development, upgrading existing devices, and geographical expansions through various strategic mergers and acquisitions. For instance, in 2015, InfuSystem Holdings, Inc. –an infusion pumps provider and related healthcare services in the U.S. and Canada –acquired Ciscura Holding Company, Inc. – a provider of ambulatory infusion pumps and healthcare services to medical facilities. Also, in 2016, ICU Medical Inc. – a developer and manufacturer of medical devices specific in the areas of vascular therapy, oncology and critical care applications – acquired Hospira Infusion Systems business from Pfizer Inc. for a total value of US$1 billion in cash and stock.

Get an exclusive discount on this report : https://www.coherentmarketinsights.com/insight/request-discount/127

Key takeaways of the market:

  • The global infusion pumps market is expected to expand at a CAGR of 6.0% during the forecast period (2016–2024). Rising prevalence of diabetes across the globe is expected to favor the infusion pumps market growth over the forecast period.

  • The analgesia application segment in the global infusion pumps market was estimated to be the largest in 2015 and is expected to retain its dominance in the market throughout the forecast period in terms of value. Increasing prevalence for chronic pain globally is expected to favor the growth for infusion pumps market in the near future. According to British journal of anesthesia, in 2013, around 20% of the European population was suffering from chronic pain.

  • In terms of product type, the insulin product type segment is expected to expand at a significant CAGR of 6.9% during the forecast period, owing to rise in population suffering from diabetes globally

  • The global infusion pumps market is characterized by strategic research and development and advancements in the technology of various medical devices including the continuous glucose monitoring device and infusion pumps.

  • Some of the major players in the global infusion pumps market include Medtronic Plc., ICU Medical Inc., Johnson & Johnson Private Ltd., Braun Melsungen AG., Smiths Medical, CareFusion Corporation, Baxter International Inc., Fresenius Kabi AG, MOOG Inc., Terumo Corporation, Nipro Corporation and Codman & Shurtleff, Inc., Infusystem

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Raj Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com

Autoimmune Disease Diagnostics Market Future Trends and Scope Analysis By 2025 |

Autoimmune Disease Diagnostics Market Overview:

The immune system of human body recognize some invaders such as bacteria, viruses, and external chemicals and attacks those to protect the body. However, sometimes the immune system attacks the healthy cells of body by considering them as foreign cells. Such a condition is called autoimmune disease. The autoimmune disease causes abnormal organ growth and changes in organ function. The genes of an individual with environmental exposure might be the major reason for autoimmune disease development. Some of the common autoimmune diseases among over 80 types of autoimmune diseases are type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis. The curing therapy for autoimmune diseases is not yet available only relieving treatments are available for this diseases. Diagnosis of the autoimmune diseases can be done by the tests which involves antinuclear antibody test, antibody test, complete blood counts and some others.

Fill the form for an exclusive sample of this report : https://www.coherentmarketinsights.com/insight/request-sample/419

The growing incidences of autoimmune diseases and government initiatives to boost the autoimmune disease diagnostics market

According to American Autoimmune Related Disease Association (AARDA), in 2016, around 50 million people suffered from autoimmune diseases in the U.S. with 75% being women. Increasing incidence of autoimmune diseases, rising public awareness and government initiatives taken to spend the budget on diagnosis and care services for autoimmune diseases, are some of the factors which are driving the autoimmune disease diagnostics market. Many of the organizations and governments are funding the research and development program for autoimmune diseases, this will help to launch the new products in the market and definitely help in the growth of autoimmune disease diagnostics industry. For instance, the discovery of novel biomarkers, which has proven to be significant to improve the diagnosis of autoimmune diseases is also one of the major factor driving the autoimmune diseases diagnostic market.

Despite of all the driving factors for the autoimmune disease diagnostics market there are some restraints which slowing down the market such as, high rate of false results, slow turnaround time for test results and lack of experience and education of laboratory personnel in the diagnostics of certain autoimmune diseases.

Aging population and technological advancements in diagnosis of rheumatoid arthritis will be the cause of growth for rheumatoid arthritis segment

The global autoimmune disease diagnostic market are segmented on the basis of disease type, test type, end user and geography

On the basis of disease type, the autoimmune disease diagnostic market is segmented into:

  • Systemic Autoimmune Disease diagnostics

  • Rheumatoid Arthritis

  • Ankylosing Spondylitis

  • Systemic Lupus Erythematosus

  • Some Others

  • Localized autoimmune disease diagnostics

  • Multiple Sclerosis

  • Type 1 diabetes

  • Hashimoto’s thyroiditis

  • Idiopathic Thrombocytopenic purpura

The high patient awareness level and large procedure volumes are the reasons that localized autoimmune disease diagnostics is dominating the overall market. Though the initiatives taken by government for patients suffering from rheumatoid arthritis and systemic lupus erythematosus will aid in the growth of systemic autoimmune disease diagnostics segment.

On the basis of test type, the global autoimmune disease diagnostic market is segmented into:

  • Antinuclear Antibody Tests

  • Autoantibody Tests

  • Complete Blood Count

  • C-reactive Protein

  • Others

On the basis of end user, the global autoimmune disease diagnostics market is segmented into

  • Hospitals

  • Diagnostics Centers

  • Research Laboratories

The technological advancements in the North America region driving the autoimmune disease diagnostics market

The regional segmentation of autoimmune disease diagnostics market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Africa and rest of the world. North America is of the largest revenue contributor in the global autoimmune disease diagnostics industry. This is mainly attributed to rising incidence of some of the common autoimmune diseases like rheumatoid arthritis and type1 diabetes. The increase in funding by government and private sector, increasing regulatory scenario monitored by World Health Organization (WHO), and technological advancements are some of the factors which are driving growth of the autoimmune disease diagnostics market in the North America region. Asia Pacific is projected to be a fast emerging region in the global autoimmune disease diagnostic market.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/419

The introduction of novel biomarkers in the market will aid in the growth of autoimmune disease diagnostic market

The key players operating the autoimmune disease diagnostics market are Abbott Laboratories, Beckman Coulter, Bio-Rad Laboratories, Euroimmun, Inova Diagnostics, Roche Diagnostics, Siemens Healthcare, A. Menarini Diagnostics, Adaptive Biotechnologies, AESKU Diagnostics, and many others. The government agencies of various countries are increasing their healthcare spending to provide better health care services, and the introduction of novel biomarkers in the research area, owing for ample opportunity for the key players, which in-turn will boost the autoimmune diseases diagnostic market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:

Mr.Shah

Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154

Tel: +1–206–701–6702

E-mail:sales@coherentmarketinsights.com

Website:https://www.coherentmarketinsights.com